Cancer Clinical Decision Tools Global Market Report 2024

The cancer clinical decision tools market size has grown rapidly in recent years. It will grow from $0.45 billion in 2023 to $0.5 billion in 2024 at a compound annual growth rate (CAGR) of 11.2%. The growth observed in the historical period can be attributed to several key factors. These include the escalating prevalence of cancer cases, the heightened complexity in cancer treatment methodologies, a growing demand for personalized medicine tailored to individual patient needs, an increased adoption of value-based healthcare models emphasizing patient outcomes, the expanding availability and utilization of comprehensive cancer-related data, and significant governmental support for cancer research and development initiatives. These elements collectively contributed to the growth and advancements in cancer care, fostering innovation and improvements in treatment strategies.

The cancer clinical decision tools market size is expected to see rapidly grown in the next few years. It will grow to $0.72 billion in 2028 at a compound annual growth rate (CAGR) of 9.6%. The anticipated growth in the upcoming period can be attributed to several key factors. These include the global aging population, fostering a heightened focus on healthcare needs and cancer care among elderly individuals. Additionally, there's an increasing emphasis on patient engagement and shared decision-making, aiming to involve patients more actively in their treatment plans. This shift towards patient-centric care is expected to shape advancements in cancer treatment methodologies.

The ascending global cancer cases are poised to fuel growth in the cancer clinical decision tools market. As highlighted by the American Cancer Society in January 2022, the US alone is estimated to witness 1.9 million new cancer diagnoses and approximately 609,360 cancer-related deaths, translating to roughly 1,670 fatalities daily. Lung, prostate, bowel, and female breast cancers collectively account for 43% of all new cancer cases worldwide. This surge in cancer incidents globally is projected to intensify the demand for cancer clinical decision tools, expediting treatment decisions and thereby bolstering the market for these tools.

The proliferation of healthcare IT adoption is anticipated to be a driving force behind the cancer clinical decision tools market. Healthcare IT adoption denotes the assimilation and usage of information technology solutions within the healthcare domain. Health institutions strategically invest in information technology, encompassing electronic health records (EHRs) and clinical decision support systems (CDSS), aiming to optimize patient care. These systems integrate real-time patient data, treatment guidelines, and alert mechanisms for potential issues, ultimately enhancing cancer treatment outcomes. For example, a report published by the Healthcare Information and Management Systems Society (HIMSS) in January 2022 indicated that a significant 80% of healthcare providers planned to augment their technology investments over the next five years. This trend in healthcare IT adoption is expected to propel the cancer clinical decision tools market's growth trajectory. Key industry players in the cancer clinical decision tools market are exploring innovative offerings like the BenchMark Ultra Plus tissue staining system to gain a competitive edge. This advanced system streamlines tissue staining, enabling quicker and more accurate pathology outcomes. Launched by F. Hoffmann-La Roche AG in June 2022, the BenchMark Ultra Plus system showcases enhanced workflow efficiency, testing processes, and sustainability attributes. This innovation empowers pathologists to deliver high-quality, time-sensitive results to medical professionals and patients alike. The BenchMark Ultra Plus system marks a significant advancement in the BenchMark series, automating erstwhile manual slide-by-slide processes and revolutionizing cancer diagnostics.

In March 2021, NeoGenomics Laboratories, Inc., an American firm specializing in cancer genetics diagnostic testing and related services, completed the acquisition of Trapelo Health, LLC., for a total of $65 million. This strategic acquisition aims to bolster NeoGenomics' capabilities in precision oncology. By leveraging Trapelo Health's innovative decision-support platform, NeoGenomics intends to streamline diagnostic and treatment selection processes for healthcare professionals, laboratories, and payers. The platform facilitates real-time access to current clinical data, expedites workflow, and enhances clinical trial matching, ultimately offering patients improved access to medically suitable therapy options.

Major companies operating in the cancer clinical decision tools market include McKesson Corporation, Medical Information Technology Inc., Philips Healthcare, Siemens Healthineers AG, Elsevier B.V., Macmillan Publishers Limited, National Decision Support Company, IBM Watson Health, Cerner Corporation, GE Healthcare, Allscripts Healthcare Solutions Inc., Epic Systems Corporation, Koninklijke Philips N.V., RaySearch Laboratories AB, Elekta AB, Varian Medical Systems Inc., Accuray Incorporated, F. Hoffmann-La Roche Ltd., Flatiron Health Inc., Tempus Labs Inc., NantHealth Inc., Syapse Inc., Inspirata Inc., Oncora Medical Inc., Prognos Health Inc., Deep 6 AI Inc., PathAI Inc., Enlitic Inc., Ibex Medical Analytics Ltd., Zebra Medical Vision Ltd., Aidoc Medical Ltd.

North America was the largest region in the cancer clinical decision tools market in 2023. The regions covered in the cancer clinical decision tools market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the cancer clinical decision tools market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada. The market for cancer clinical decision tools consists of sales of risk assessment tools, Q-Cancer tools, and MacMillan’s cancer decision tool. Values in this market are ‘factory gate values,’ that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Among the primary types of cancer clinical decision tools are risk assessment tools (RAT) and Qcancer. Risk assessment tools evaluate a combination of risk factors, encompassing genetic, environmental, and behavioral elements, to translate these factors into estimations of an individual's likelihood of developing specific types of cancer. These tools serve to streamline risk models and facilitate assessments of an individual's cancer risk profile. These cancer clinical decision tools find application across various healthcare settings, including hospitals and clinics, supporting healthcare professionals in making informed decisions regarding patient care and potential referrals for further diagnostic assessments.

The cancer clinical decision tools market research report is one of a series of new reports provides cancer clinical decision tools market statistics, including cancer clinical decision tools industry global market size, regional shares, competitors with a cancer clinical decision tools market share, detailed cancer clinical decision tools market segments, market trends and opportunities, and any further data you may need to thrive in the cancer clinical decision tools industry. This cancer clinical decision tools market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.